Pazopanib Clinical Trials

6 actively recruiting trials across 3 locations

▲ +1 trial since July 2026

Also known as: GW786034, VOTRIENT®, Votrient, Votrient®

Pipeline

Phase 1: 1Phase 2: 2Phase 3: 1Phase 1/2: 1

Top Sponsors

M.D. Anderson Cancer Center2
Xynomic Pharmaceuticals, Inc.1
St. Jude Children's Research Hospital1
Shandong Cancer Hospital and Institute1
Imbioray (Hangzhou) Biomedicine Co., Ltd.1

Indications

Cancer6
Dermatofibrosarcoma Protuberans, Fibrosarcomatous1
Low Grade Myofibroblastic Sarcoma1
Giant Cell Tumor of Soft Parts NOS1
Round Cell Sarcoma1

Other2 trials

A Study of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell Carcinoma

Phase 2

Evaluation of the Efficacy and Safety of Pazopanib in Combination with TGI/CIV for Recurrent or Refractory Rhabdomyosarcoma in Children or Adolescents

Phase 2

Houston, Texas2 trials

A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue Sarcomas

The University of Texas M. D. Anderson Cancer Center

Phase 1

Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma

M D Anderson Cancer Center

N/A

Phoenix, Arizona1 trial

A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)

University Of UA Cancer Center(UACC)/DH-SJHMC

Phase 3

Atlanta, Georgia1 trial

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

Children's Healthcare of Atlanta

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.